CTS

CERETASLTD FPO [CTS]

Ceretas Limited engages in developing a portable and non-invasive therapeutic ultrasound platform for the treatment of Alzheimer's disease and other neurodegenerative conditions in Australia. The company offers a device that uses focused ultrasound beams directed through the skull to interact non-invasively with brain tissue. The company's technology operates through two primary mechanisms, including neuromodulation, which uses low-intensity focused ultrasound to stimulate neural circuits; and BBBO, which temporarily and reversibly opens the blood-brain barrier using ultrasound combined with circulating microbubbles that facilitates brain's natural clearance of amyloid-beta and tau and helps delivery of co-administered drugs to targeted brain regions. The company was incorporated in 2024 and is based in Brisbane, Australia.